Generate Biomedicines Inc logo

Generate Biomedicines Inc

GENB
Healthcare|Biotechnology|USA
$14.32
-1.40 (-8.87%)

Financials

Financial Snapshot

Market Cap
$1.84B
Enterprise Value
$160.2M
Revenue (TTM)
$31.9M
Net Income (TTM)
$-203.2M
Cash & Equivalents
—
Net Cash/Share
$-5.69
Free Cash Flow (TTM)
$-204.1M
Operating CF (TTM)
$-200.6M
Debt/Equity
-0.11

Cash Runway & Burn Rate

Cash on Hand
$0.00
Quarterly Burn
$50.2M
Monthly Burn
$16.7M
Est. Runway
—
MetricTrend20242025TTM
Cash & Investments
$393.6M$221.5M$221.5M
Operating Cash Flow
$-117.8M$-200.6M$-200.6M
Free Cash Flow
$-121.2M$-204.1M$-204.1M
Capital Expenditure
$-3.4M$-3.5M$-3.5M
Financing Cash Flow
$91.3M$28.1M$28.1M

R&D Spending

R&D (TTM)
$224.7M
R&D Intensity
704.5%
R&D Growth YoY
+0.0%
MetricTrend20242025TTM
Revenue
$20.5M$31.9M$31.9M
R&D Expense
$175.3M$224.7M$224.7M
R&D % of Revenue
856.9%704.5%704.5%
SG&A
$42.1M$42.3M$42.3M

Income Statement

MetricTrend20242025TTM
Revenue
$20.5M$31.9M$31.9M
Cost of Goods Sold
$0.00$0.00$0.00
Gross Profit
$20.5M$31.9M$31.9M
R&D
$175.3M$224.7M$224.7M
SG&A
$42.1M$42.3M$42.3M
Operating Income
$-196.9M$-235.1M$-235.1M
Interest Expense
$-2.1M$-1.1M$-1.1M
Pretax Income
$-181.2M$-222.8M$-222.8M
Net Income
$-173.8M$-203.2M$-203.2M
EPS (Diluted)
-2.09-2.18-2.18
EBITDA
$-163.7M$-208.5M$-208.5M
Shares Out. (M)
102.31102.31102.31

Balance Sheet

MetricTrend20242025TTM
Cash & Equivalents
$176.3M$121.7M$121.7M
Marketable Securities
$217.4M$99.8M$99.8M
Total Current Assets
$407.5M$234.4M$234.4M
Total Assets
$518.3M$330.2M$330.2M
Total Current Liabilities
$86.6M$82.2M$82.2M
Long-Term Debt
$0.00$0.00$0.00
Total Liabilities
$953.3M$953.4M$953.4M
Stockholders' Equity
$-434.5M$-616.0M$-616.0M
Retained Earnings
$-473.1M$-676.3M$-676.3M

Cash Flow Statement

MetricTrend20242025TTM
Operating Cash Flow
$-117.8M$-200.6M$-200.6M
Capital Expenditure
$-3.4M$-3.5M$-3.5M
Free Cash Flow
$-121.2M$-204.1M$-204.1M
Investing Cash Flow
$-57.7M$116.8M$116.8M
Financing Cash Flow
$91.3M$28.1M$28.1M
Issuance of Stock
$0.00$0.00$0.00
Repurchase of Stock
$0.00$0.00$0.00
Issuance of Debt
$0.00$0.00$0.00
Payments of Debt
$-11.1M$-8.2M$-8.2M
Stock Based Comp.
$19.5M$20.6M$20.6M
Net Change in Cash
$-84.1M$-55.8M$-55.8M

Dilution Tracker

Shares Outstanding
102M
5-Year Share Growth
+0.0%
Stock Issuance (TTM)
$0.00
MetricTrend20242025TTM
Shares Out. (M)
102.31102.31102.31
YoY Change %
—0.0%0.0%
Stock Issuance
$0.00$0.00$0.00
Stock Repurchase
$0.00$0.00$0.00
Stock Based Comp.
$19.5M$20.6M$20.6M

Margins & Profitability

MetricTrend20242025TTM
Gross Margin %
0.0%0.0%0.0%
Operating Margin %
-962.6%-737.0%-737.0%
Net Margin %
-849.4%-637.0%-637.0%
EBITDA Margin %
-800.2%-653.7%-653.7%
FCF Margin %
-592.4%-640.1%-640.1%
ROE %
0.0%0.0%0.0%
ROA %
-33.5%-47.9%-47.9%
R&D / Revenue---

Valuation

P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S45.91
Historical— / — / 45.91
Industry Med.9.49
P/B—
Historical— / — / —
Industry Med.2.93
EV/EBITDA-6.61
Historical-6.61 / — / —
Industry Med.13.02
EV/Revenue43.21
Historical— / — / —
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13

Intrinsic Value Models

MetricTrend20242025TTM
PE RatioN/AN/AAt Loss
PS Ratio
0.000.0045.91
PB Ratio
0.000.000.00
EV/EBITDA
0.000.00-6.61
EV/Revenue
0.000.0043.21

Analyst Estimates & Quality

Altman Z-Score
—
Distress
Piotroski F-Score
N/A
Weak
Beneish M-Score
—
Possible Manipulator

Forward Estimates

MetricCurrent YearNext Year2 Years Out
Revenue$31.07M$34.50M$122.97M
Net Income$-270.97M$-291.16M$-256.83M
EPS-2.37-2.28-2.36
Book Value per Share3.143.342.83
Operating Cash Flow per Share0.000.000.00
Operating CF$0.00M$0.00M$0.00M

Dividends

Revenue Segments

By Business

Segment2025
Field of generative biology by using machine learning for drug discovery and development through the$31.9M

By Geography

Segment2025
United States$31.9M